68Ga- and 64Cu-NODAGA-E[c(RGDyK)]2 PET Tracers for Angiogenesis Imaging
Summary
Rigshospitalet filed patent application US20260108638A1 disclosing two novel PET tracers — 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 — for clinical imaging of neo-angiogenesis in humans. The application (No. 19413437) was published April 23, 2026 under CPC classification A61K 51/0482, with inventors Andreas Kjær, Jacob Madsen, Malene Brandt-Larsen, and Jytte Oxboel listed. The abstract claims both Ga-68 and Cu-64 chelates bound to the NODAGA-E[c(RGDyK)]2 targeting moiety for diagnostic PET applications.
“There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108638A1 filed by Rigshospitalet, disclosing two angiogenesis PET tracer compositions: 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2. The application claims these radiopharmaceuticals for imaging neo-angiogenesis in human patients. The filing date is December 9, 2025, with the publication date April 23, 2026.
For pharmaceutical and biotech companies developing targeted radiopharmaceuticals or PET imaging agents, this application indicates continued activity in the integrin-targeting (RGD motif) PET tracer space. Companies with competing angiogenesis imaging programs or those licensing similar targeting vectors should review their IP positions against this application's claims.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
68GA- AND 64CU -NODAGA-E[C(RGDYK)]2 FOR USE AS PET TRACERS IN THE IMAGING OF ANGIOGENESIS IN HUMANS
Application US20260108638A1 Kind: A1 Apr 23, 2026
Assignee
RIGSHOSPITALET
Inventors
Andreas KJAER, Jacob MADSEN, Malene BRANDT-LARSEN, Jytte OXBOEL
Abstract
There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.
CPC Classifications
A61K 51/0482
Filing Date
2025-12-09
Application No.
19413437
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.